Usnic acid
Based on 2 publication(s) in Google Scholar
Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase.
For research use only. We do not sell to patients.
- Purity : 99.40%
- CAS No.: 125-46-2
- Formula: C18H16O7
- Molecular Weight:344.32
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Usnic acid
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>10 μM
Compound: (-)-1
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31282672] |
| MCF7 | IC50 |
>10 μM
Compound: (-)-1
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31282672] |
| PC-3 | IC50 |
>10 μM
Compound: (-)-1
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31282672] |
| PC-3 | IC50 |
>10 μM
Compound: (-)-1
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31282672] |
In Vitro
Usnic acid (0-40 μg/mL, 0-150 min) inhibits the growth of B. subtilis, S. aureus and V. harveyi[1].
Usnic acid (0.5/1 μg/mL, 15-150 min) inhibits the incorporation rate of DNA, RNA and protein synthesis macromolecular precursors thymidine, uridine and leucine in B. subtilis and S. aureus[1].
Usnic acid (25-100 μM, 24-48 h) inhibits the viability and clonogenicity of A549 cells. It also induces G0/G1 cell cycle arrest, mitochondrial membrane depolarization and apoptosis of A549 cells[2].
Usnic acid (0.3-3 μM, 4 d) inhibits the differentiation of bone marrow-derived macrophages (BMM) into mature osteoclasts in a dose-dependent manner[4].
Usnic acid (3 μM, 0-3 d) inhibits the transcriptional and translational expression of RANKL on NFATc1 in BMMs[4].
Usnic acid (3 μM, 5-30 min) inhibits RANKL-induced activities of MAP kinases p38, ERK and JNK in BMMs[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24/48 h
-
Result:Inhibited cell proliferation (35-48%/59-72%).
-
Cell Line:A549 cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:7 days
-
Result:Inhibited cell colony formation (8, 23, 85%).
-
Cell Line:A549 cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24/48 h
-
Result:Induced cell cycle arrest at G0/G1 (77%, 81% and 80%; 87%, 85%, and 82%).
Down-regulated CDK4, CDK-6 and cyclin D1 protein levels.
Up-regulated p21/Cip1 protein and cleaved-PARP levels.
-
Cell Line:A549 cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:48 h
-
Result:Increased the number of apoptotic cells (6%, 10% and 11%).
-
Cell Line:BMMs
-
Concentration:Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) and M-CSF (30 ng/mL) stimulation
-
Incubation Time:0, 1, 2, 3 d
-
Result:Down-regulated the gene expression levels of TRAP, DC-STAMP, and cathepsin K.
-
Cell Line:BMMs
-
Concentration:Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) stimulation
-
Incubation Time:5, 15, 30 min
-
Result:Down-regulated the protein expression levels of p38, ERK and JNK.
In Vivo
Usnic acid (1 μg/g, i.p., every day for up to 8 days) inhibited osteoclastic bone resorption in the lipopolysaccharide (LPS) bone erosion model [4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Indomethacin-induced gastric damage model (male, Albino-Wistar rats, weighing 180-190 g; Indomethacin 25 mg/kg body weight orally.)[3]
-
Dosage:25, 50, 100 and 200 mg/kg
-
Administration:Oral gavage (p.o.), once
-
Result:Reduced gastric damage in rats (80.2-96.4%).
Increased SOD, GPx, GSH and cNOS levels.
Reduced CAT, GR, LPO, iNOS and MPx levels.
-
Animal Model:LPS-induced mouse bone erosion model (five-week-old male ICR mice, 5 µg/µL LPS was injected intraperitoneally on days 1 and 4)[4]
-
Dosage:1 μg/g
-
Administration:Intraperitoneal injection (i.p.), every day for up to 8 days
-
Result:Increased BMD and BV/TV.
Reduced BS/TV and Tb.Sp.
Chemical Information
-
CAS No. 125-46-2
-
Appearance Solid
-
Molecular Weight 344.32
-
Formula C18H16O7
-
Color White to yellow
-
SMILES
O=C(C1(C)C(OC2=C(C(C)=O)C(O)=C(C)C(O)=C12)=C3)C(C(C)=O)C3=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvent & Solubility
In Vitro:
DMSO : 3.33 mg/mL (9.67 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 9.8 mg/mL (28.46 mM); Suspended solution; Need ultrasonic
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Purity & Documentation
-
Data Sheet (306 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Maciąg-Dorszyńska M, et al. Antibacterial activity of lichen secondary metabolite usnic acid is primarily caused by inhibition of RNA and DNA synthesis. FEMS Microbiol Lett. 2014 Apr;353(1):57-62. [Content Brief]
[2]. Singh N, et al. Usnic acid inhibits growth and induces cell cycle arrest and apoptosis in human lung carcinoma A549 cells. Nutr Cancer. 2013;65 Suppl 1:36-43. [Content Brief]
[3]. Odabasoglu F, et al. Gastroprotective and antioxidant effects of usnic acid on indomethacin-induced gastric ulcer in rats. J Ethnopharmacol. 2006 Jan 3;103(1):59-65. [Content Brief]
[4]. Kim KJ, et al. Effect of Usnic Acid on Osteoclastogenic Activity. J Clin Med. 2018 Oct 12;7(10):345. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | 72.6069 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | 14.5214 mL |